[2015-Jan-29] Approval of Evotaz, containing 300 mg of atazanavir and 150 mg of cobicistat

[2015-Jan-29] HIV/AIDS Update - Approval of Evotaz, containing 300 mg of atazanavir and 150 mg of cobicistat

http://content.govdelivery.com/accounts/USFDA/bulletins/ed4095

Evotaz.cdx

Brett S. Robinson, Keith A. Riccardi, Yi-fei Gong, Qi Guo, David A. Stock, Wade S. Blair, Brian J. Terry, Carol A. Deminie, Fred Djang, Richard J. Colonno, and Pin-fang Lin, BMS-232632, a Highly Potent Human Immunodeficiency Virus Protease Inhibitor That Can Be Used in Combination with Other Available Antiretroviral Agents, Antimicrob. Agents Chemother., 2000, 44 (8), pp 2093-2099

http://dx.doi.org/10.1128/AAC.44.8.2093-2099.2000

Katherine F. Croom, Sohita Dhillon, and Susan J. Keam, Atazanavir, Drugs, 2009, 69 (8), pp 1107-1140

http://dx.doi.org/10.2165/00003495-200969080-00009

Lianhong Xu, Hongtao Liu, Bernard P. Murray, Christian Callebaut, Melody S. Lee, Allen Hong, Robert G. Strickley, Luong K. Tsai, Kirsten M. Stray, Yujin Wang, Gerry R. Rhodes and Manoj C. Desai, Cobicistat (GS-9350): A Potent and Selective Inhibitor of Human CYP3A as a Novel Pharmacoenhancer, ACS Med. Chem. Lett., 2010, 1 (5), pp 209–213

http://dx.doi.org/10.1021/ml1000257

Eve-Irene Lepist, Truc K. Phan, Anupma Roy, Leah Tong, Kelly MacLennan, Bernard Murray and Adrian S. Ray, Cobicistat Boosts the Intestinal Absorption of Transport Substrates, Including HIV Protease Inhibitors and GS-7340, In Vitro, Antimicrob. Agents Chemother., 2012, 56 (10), pp 5409-5413

http://dx.doi.org/10.1128/AAC.01089-12